An assessment by the Statin Diabetes Safety Task Force: 2014 update

Slides:

Advertisements

Similar presentations

TREATING LIPIDS FOR PREVENTION OF CAD : HOW AGGRESSIVE SHOULD WE BE? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration.

Advertisements

Cholesterol quintile (mg/dL)

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.

The overwhelming case for LDL-C lowering

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention of Cardiovascular Mortality and.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:

Date of download: 6/26/2016 From: Lipid-Lowering Therapy in Persons With Chronic Kidney Disease: A Systematic Review and Meta- analysis Ann Intern Med.

Double-blind, randomized trial in 4,162 patients with Acute Coronary Syndrome

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.

Baseline characteristics of HPS participants by prior cerebrovascular disease.

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Cholesterol Treatment Trialists’ (CTT) Collaboration Slide deck

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Cholesterol Lowering and CV Risk: Meta-analyses

From Inuit to Implementation: Omega-3 Fatty Acids Come of Age

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps Kevin C. Maki, PhD,

The Anglo Scandinavian Cardiac Outcomes Trial

Establishing the benefit of statins in low-to-moderate—risk primary prevention: The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Mechanisms, Clinical Significance, and Prevention of Cognitive Impairment in Patients With Atrial Fibrillation Lena Rivard, MD, MSc, Paul Khairy, MD,

Microalbuminuria: target for renoprotective therapy PRO

The following slides highlight a presentation at the Late-Breaking Clinical Trials session of the American Heart Association Scientific Sessions, November.

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

An International Atherosclerosis Society Position Paper: Global recommendations for the management of dyslipidemia-Full report Scott M. Grundy, Hidenori.

Microalbuminuria: target for renoprotective therapy PRO

Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene? Sumeet Gupta, MPharm, PhD,

Omega-3 Fatty Acids for Cardioprotection

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report Terry A. Jacobson, MD, Matthew K. Ito,

Postoperative tricuspid regurgitation after adult congenital heart surgery is associated with adverse clinical outcomes Matthew J. Lewis, MD, MPH, Jonathan.

Cardiovascular Disease Resulting From a Diet and Lifestyle at Odds With Our Paleolithic Genome: How to Become a 21st-Century Hunter-Gatherer James H.

A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality Rishi K. Wadhera,

Apolipoprotein E-containing high-density lipoprotein (HDL) modifies the impact of cholesterol-overloaded HDL on incident coronary heart disease risk:

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Jonathan C. Cohen, PhD Journal of Clinical Lipidology

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?

An assessment by the Statin Intolerance Panel: 2014 update

Task-sharing interventions for cardiovascular risk reduction and lipid outcomes in low- and middle-income countries: A systematic review and meta-analysis

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States Sudhir K. Unni, PhD, MBA, Ruben G.W.

Todd R. Vogel, MD, MPH, Viktor Y. Dombrovskiy, MD, PhD, MPH, Paul B

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned Robert E.

LDL - How low can you go? Terry Jacobsen, MD

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

From Inuit to Implementation: Omega-3 Fatty Acids Come of Age

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Delahoy PJ, et al. Clin Ther 2009;31:236-44

Brugts JJ, et al. BMJ 2009;338:b2376.

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies.

Increase of physical activity over time associated with lower HF risk

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

An assessment by the Statin Diabetes Safety Task Force: 2014 update Kevin C. Maki, PhD, FNLA, Paul M. Ridker, MD, MPH, W. Virgil Brown, MD, FNLA, Scott M. Grundy, MD, PhD, FNLA, Naveed Sattar, MD, PhD Journal of Clinical Lipidology Volume 8, Issue 3, Pages S17-S29 (May 2014) DOI: 10.1016/j.jacl.2014.02.012 Copyright © 2014 National Lipid Association Terms and Conditions

Figure 1 Association between statin therapy and incident diabetes in 13 major cardiovascular trials. AFCAPS/TEXCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; ASCOT-LLA, Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm; CI, confidence interval; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; GISSI HF, Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca; GISSI PREV, Gruppo Italiano per lo Studio della Sopravvivenza nell Insufficienza Prevenzione; HPS, Heart Protection Study; JUPITER, Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin; LIPID, Long-term Intervention with Pravastatin in Ischemic Disease; MEGA, Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese; OR, odds ratio; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; 4S, Scandinavian Simvastatin Survival Study; WOSCOPS, West of Scotland Coronary Prevention Study. Permission to reuse this figure was granted by Elsevier.13 Journal of Clinical Lipidology 2014 8, S17-S29DOI: (10.1016/j.jacl.2014.02.012) Copyright © 2014 National Lipid Association Terms and Conditions

Figure 2 Risk of developing new-onset diabetes and CV events according to the number of diabetes risk factors at baseline in the Treating to New Targets and Incremental Decrease in Endpoints Through Aggressive Lipid Lowering statin trials. Atorva, atorvastatin; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; simva, simvastatin. Permission to reuse this figure was granted by Elsevier.18 Journal of Clinical Lipidology 2014 8, S17-S29DOI: (10.1016/j.jacl.2014.02.012) Copyright © 2014 National Lipid Association Terms and Conditions